澳洲幸运5官方开奖结果体彩网

Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows

By 澳洲幸运5官方开奖结果体彩网:Andrew Kessel
Published August 01, 2024
12:02 PM EDT
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana

Scott Olson / Getty Images

Key Takeaways

  • Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro and obesity medication Zepbound, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 trial.
  • Participants also saw a 15.7% reduction in body weight.
  • Eli Lilly plans to submit the study results to the FDA later this year.

The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment.

Tirzepatide, sold as Mounjaro to treat Type 2 diabetes and Zepbound for obesity, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 clinical trial, the company said Thurs💫day. 

The SUMMIT trial evaluated the safety and efficacy of the drug in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In add𒈔ition to improved heart failure outcomes, participants also saw an average of 15.7% reduction in body weight, compared with 2.2% for pla🀅cebo. 

Eli Lilly said it plans to submit the results of the trial to the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) and other regulators later this year. 

Shares of the drugmaker rose nearly 3% to $826.98 as of noon ET Thursday. They are up more than 40% this year.

Do you have a news tip for Investopedia reporters? Please email us at
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. Eli Lilly and Company. “”

Compare Accounts
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.
Read more

Related Articles

An Eli Lilly & Co. Zepbound injection pen
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Zepbound injection pen container on a shelf.
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for ꦜSelf-Pay Patients
A white, green, and purple Zepbound injection pen on a table in front of a box for the medication
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
AbbVie logo seen displayed on a monitor
AbbVie Joins Obesity Treatment Market With Up to $2.2B♒ Licensing♓ Deal
An injector pen of Zepbound on top of a white and green box for the drug
L𝕴illy Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
The blue Novo Nordisk logo is seen on a group of white flags around tree branches and a blue sky.
Novo Nordisk Shares Si🗹nk on Latest Ca⛎griSema Weight Loss Drug Study
Eli Lilly headquarters in Indianapolis
Eli Lilly Latest US Compan🎃y to Commit to Domestic Investments
A sign for the Eli Lilly Corporate Center is seen outside a brown office building.
Eli༒ Lilly Stock Tumbles as Q3 Sales, Profits Fal👍l Well Short of Estimates
Eli Lilly
What Analysts Think of E෴♕li Lilly Stock Ahead of Earnings
Roche sign
Roch🎀e Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
The red "Lilly" logo is seen on the side of a building with a blue sky and clouds in the background.
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Close-up of a patient using an Eli Lilly & Co. Zepbound injection pen.
Why Eli𓂃 Lilly Stock Jumped to a Record High on Tuesday
The Novo Nordisk A/S logo on a wall at their pharmaceutical manufacturing facility in Hillerod, Denmark
Novo Nordisk Stock Ju𝔉mps on Early Stage Weight-Loss Drug Trial Results
Woman standing on electronic scale.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
A group of scientists work together in a laboratory.
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
Popular weight-loss drugs Wegovy, Ozempic, and Mounjaro
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss ꦺDrugs